Biogen and Bio-Thera Reveal Tocilizumab Progress
Biosimilar Actemra Phase III Results Trigger $30m Payment Under April Deal
Biogen and Bio-Thera Solutions have reported positive results from a Phase III trial for their BAT1806 proposed biosimilar tocilizumab rival to Actemra. The milestone has triggered a $30m payment from Biogen under the pair’s development deal.
You may also be interested in...
Biogen and Bio-Thera have revealed positive Phase III data for their proposed tocilizumab biosimilar rival to Actemra/RoAcetmra.
Sandoz has plugged another gap in its off-patent oncology pipeline, from which the company has rolled-out four marketed oncology biosimilars, by bringing in Bio-Thera Solutions’ BAT1706 proposed biosimilar to Avastin, including in the US and Europe.
Fresenius Kabi has reported positive Phase I data for its MSB11456 proposed tocilizumab biosimilar rival to Actemra/Ro-Actemra, against the backdrop of shortages for the brand which is being used in some regions to treat COVID-19.